Lilly Earnings Call Analysis: Why Zepbound Missed Earnings
Listen now
Description
Send us a textDave brings his analysis of the Q3 Eli Lilly earnings call, and how it relates to the future of access to obesity medicine. Also there is an important clarification on the Zepbound savings card that you should not miss.#Zepbound #Mounjaro #TirzepatideOnthepen.TVSupport the showDNF10 Peptide Supplement I Use: https://integrativepeptides.com/AFFILITATES/OTPUSE CODE "OTP10" to save 10%. A small commission is paid back to support On The Pen!MY WORK RELIES ON YOUR GENEROSITY, WAYS TO...
More Episodes
Send us a textIn this episode of On The Pen: The Weekly Dose, host Dave Knapp dives into the latest updates in obesity medicine, with insightful takes on current treatment breakthroughs, new medication approvals, and tips on navigating healthcare options. This week’s deep dive also touches on...
Published 11/12/24
Send us a textSemaglutide News: https://www.onthepen.com/post/select-trial-update-semaglutide-s-cardiovascular-benefits-and-psychiatric-safety-profile-highlighteViking Therapeutics News:https://www.onthepen.com/post/vk2735-vikingtideAstraZeneca News:...
Published 11/05/24
Published 11/05/24